ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Editas Medicine Inc

Editas Medicine Inc (EDIT)

5.54
0.00
(0.00%)
Closed July 15 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.54
Bid
5.45
Ask
5.54
Volume
-
0.00 Day's Range 0.00
4.45 52 Week Range 11.69
Market Cap
Previous Close
5.54
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,126,832
Shares Outstanding
82,237,974
Dividend Yield
-
PE Ratio
-2.97
Earnings Per Share (EPS)
-1.86
Revenue
78.12M
Net Profit
-153.22M

About Editas Medicine Inc

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Editas Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EDIT. The last closing price for Editas Medicine was $5.54. Over the last year, Editas Medicine shares have traded in a share price range of $ 4.45 to $ 11.69.

Editas Medicine currently has 82,237,974 shares outstanding. The market capitalization of Editas Medicine is $455.60 million. Editas Medicine has a price to earnings ratio (PE ratio) of -2.97.

EDIT Latest News

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean...

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.9420.43478260874.65.764.617025375.18126829CS
40.438.414872798435.115.764.4524915544.96713532CS
12-0.05-0.8944543828265.596.694.4521268325.30547843CS
26-3.41-38.10055865928.9511.584.4519851896.66306151CS
52-3.04-35.43123543128.5811.694.4518214857.67771236CS
156-36.64-86.865813181642.1873.0254.45178358415.36392355CS
260-19.44-77.822257806224.9899.954.45159211824.4712156CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0

EDIT Discussion

View Posts
Monksdream Monksdream 1 week ago
EDIT under $5
πŸ‘οΈ0
Monksdream Monksdream 2 weeks ago
EDIT new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 2 weeks ago
EDIT new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
EDIT new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 4 weeks ago
Looking at HbF levels, EDIT-301 appears to achieve slightly higher levels than Casgevy. For total Hb levels, EDIT-301 seems to outperform Casgevy https://finance.yahoo.com/news/editas-medicine-announces-safety-efficacy-070000921.html

However, the ongoing trials and launch are going to be costly, and they aren't working on busulfan free conditioning.
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
EDIT under $10
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
Dr. Liu moved on with base and prime editing and just left the company to die on the vine.
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
EDIT under $10
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
EDIT new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
EDIT new 52 lo

πŸ‘οΈ0
Monksdream Monksdream 3 months ago
EDIT new 52 lo
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Could be upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=25899

If so, CRSP and NTLA have already disclosed preclinical data for in vivo editing.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Does this have any FDA approvals?

No. Plus they are currently focusing on TDT and SCD, both early stage, and both indications becoming more crowed. Also, CRSP should get FDA and EMA approvals for exa-cel in those indications and should have at least five years head start over others.

Will Precision Biosciences be this high or higher?

If the clinical data they present in April/May is good, I expect the SP will increase, but not as high as this. They (DTIL) will also have an upcoming R&D Day (focusing on in vivo programs) mid-year.

How do the two compare?

There are a number of differences. One example, DTIL have yet to show they can do in vivo editing in humans. Another, both have broad plans for in vivo programs, but delivery outside the liver (using current AAVs for many indications) can be problematic.
πŸ‘οΈ0
rtrstock rtrstock 1 year ago
Does this have any FDA approvals? Will Precision Biosciences be this high or higher? How do the two compare?
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
PR https://www.globenewswire.com/news-release/2022/05/18/2445810/0/en/Editas-Medicine-Presents-Data-on-SLEEK-Gene-Editing-Technology-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

Posters https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT2022-EDIT-103-Liu-Presentation.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-2022-SLEEK-Zuris.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Kahn-EDIT202-Poster.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Duke-EDIT-101-Immunogenicity-Oral-Presentation.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
1106: EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2005

831: SLEEK: A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next-generation Cell-based Medicines https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1751
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
ASGCT title:

EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing.
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
PR https://www.bloomberg.com/press-releases/2022-04-08/editas-medicine-reports-engineered-ink-cell-preclinical-data-at-american-association-for-cancer-research-annual-meeting

Poster https://www.editasmedicine.com/wp-content/uploads/2022/04/AACR_2022_Poster_FINAL.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
AACR abstract

AsCas12a gene-edited iPSC-derived NK cells constitutively expressing CD16 and membrane-bound IL-15 demonstrate prolonged persistence and robust anti-tumor activities in a solid tumor mouse model https://www.abstractsonline.com/pp8/#!/10517/presentation/16690
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
ASH PR https://www.globenewswire.com/news-release/2021/12/12/2350352/0/en/Editas-Medicine-Reports-Preclinical-Data-Demonstrating-Robust-Tumor-Reduction-and-Clearance-Using-Novel-Engineered-iNK-Cells-at-the-American-Society-of-Hematology-Annual-Meeting.html

Poster https://www.editasmedicine.com/wp-content/uploads/2021/12/ASH_2021_iNK_poster_presentation.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
From the PR: In these experiments, iPSCs were edited using the Company’s SLEEK gene editing technology at the GAPDH locus with a proprietary, Editas-engineered AsCas12a nuclease to knock-in high-affinity CD16 and membrane bound IL-15. iPSC clones were then differentiated into iNKs that were confirmed to express high levels of CD16 and IL-15. Increasing NK cell CD16 expression can improve anti-tumour activity when combined with antibody-dependent cell-mediated cytotoxicity (ADCC)-enabling antibodies. IL-15 is important for NK cell survival, and increasing IL-15 expression prolongs the persistence of NK cells. Knock-in of IL-15 may also eliminate the need to administer cytokines systemically, which can cause severe toxicity.

Results demonstrated that the edited iNK cells exhibited enhanced serial tumour cell killing through ADCC in a2D assay against SKOV-3 ovarian cancer cells and in a 3D tumour spheroid killing assay. The edited iNK cells were also able to persist for a dramatically longer period of time relative to unedited iNK cells. Together, these data provide strong support for the continued development of engineered iPSC derived iNK cells as a potential novel class of therapeutics targeting solid tumours.

''In this promising new research, we demonstrate the use of our proprietary SLEEK technology to knock-in both CD16 and IL-15 into iNK cells. The engineered cells demonstrated potent anti-tumour activity and substantially increased persistence without systemic cytokines, an important limitation with many existing NK cell approaches. We also believe this to be a potentially safer and more reliable approach to developing next generation NK cell therapy medicines because through our iPSC development process, we only select cell clones that have exactly the desired on-target edits, thereby avoiding the possibility of cell abnormalities being introduced,'' said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. ''NK cells are great candidates for off-the-shelf immunotherapy medicines given their high tumour killing capacity and their low propensity for graft-versus-host disease, and we believe these data provide evidence for the potential of future experimental medicines from our iNK program to exert enhanced anti-tumour activity in the clinic in the treatment of solid tumours.''
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
SITC poster https://www.editasmedicine.com/wp-content/uploads/2021/11/SITC_2021_CD16mbIL-15_KI_iNKs_poster_FINALv.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
ASH abstracts

Deletion of CISH and TGFßR2 in iPSC-Derived NK Cells Promotes High Cytotoxicity and Enhances In Vivo Tumor Killing https://ash.confex.com/ash/2021/webprogram/Paper150731.html

Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of Transfusion Dependent Beta Thalassemia https://ash.confex.com/ash/2021/webprogram/Paper149956.html
πŸ‘οΈ0
IH Market Vision [Andrew] IH Market Vision [Andrew] 3 years ago
GRTS and EDIT Biotech Stock Plays Update | Big Events Coming Up!

I chat about some recent events and news with Gritstone ($GRTS) and Editas ($EDIT) - two very exciting biotechnology companies doing work in a variety of treatments like immunotherapy & gene editing.



Watch on YouTube
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Initial clinical data for 101 is planned later this month. The data will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit. The presentation will cover cumulative data from patients in the adult low-dose and mid-dose cohorts. As required by the trial protocol, all patients are monitored every three months for the first year and at various timepoints for another two years.
πŸ‘οΈ0
IH Market Vision [Andrew] IH Market Vision [Andrew] 3 years ago
Editas ($EDIT) has a Big Event Coming Up! | Gene Editing Biotech

Editas ($EDIT) has got a big event on September 27th, and I decided to ride the wave and share my thoughts as to why. Events are king in biotechs. Tell us what you think about our new series! Is this the kind if info you would be looking for? What other DD should we add?

Watch the Video on Youtube



πŸ‘οΈ0
Scott 75 Scott 75 3 years ago
Thank you for the explanation and your time. Have a good weekend.
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Cancer is highly complex, so multiplexed gene editing will be needed to generate better cell therapies. One of the benefits of CRISPR is the ability to knockout multiple genes with (very) high efficacy, but that has not been the case for knock-ins. Now with this approach, it seems to have been overcome. If you take HLA-E, the efficacy (for knock-in) was over 88%, and this should 'shield' the majority of cells from being rejected by the patient they would be given to. ADAP will use the same approach for its iPSC-derived TCR-T cell therapies https://www.nature.com/articles/nbt.3860
πŸ‘οΈ0
Scott 75 Scott 75 3 years ago
Wow that sounds so?? What the heck does any of that mean?
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
''New preclinical data demonstrated that SLEEK results in the knock-in of multiple clinically relevant transgenes through a proprietary process that selects for cells containing the knock-in cargo. In addition, high percentage knock-in efficiencies were enabled by Editas Medicine’s proprietary engineered AsCas12a nuclease. More than 90 percent knock-in efficiencies were observed in various clinically relevant target cells, including iPSCs, T cells, and NK cells. Additionally, SLEEK may be used to fine-tune the expression levels of transgene cargos, an important attribute of next-generation cell therapy medicines.'' https://www.globenewswire.com/news-release/2021/08/20/2284285/0/en/Editas-Medicine-Presents-Data-on-New-SLEEK-Gene-Editing-Technology-at-Cold-Spring-Harbor-Laboratory-s-Genome-Engineering-CRISPR-Frontiers-Meeting.html

Slides https://www.editasmedicine.com/wp-content/uploads/2021/08/2021_CSHL-CRISPR-Frontiers-SLEEK-Zuris_FINAL.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
New preclinical data https://www.nature.com/articles/s41467-021-24017-8
πŸ‘οΈ0
Gpheart2016 Gpheart2016 3 years ago
Not sure what happened in the last hour, but the genomic stocks have all exploded upwards! EDIT is up 21% today. CRSP AND NTLA are making similar moves. I don’t know what triggered it, but good news for sure.
πŸ‘οΈ0
go_glortho go_glortho 3 years ago
For sure! I've been in NTLA, EDIT and ARCT for a while just waiting for the CRSPR-Cas9 technology to be shown to be effective. We're just about there. If they don't explode in 2021, we should see it in 2022 the latest with all of the potentially great results from this technology!
πŸ‘οΈ0
Gpheart2016 Gpheart2016 3 years ago
Here we go! Gene editing stocks will be hot again. EDIT, CRSP, NTLA are going to be flying high. And this is technology that will be the future of medicine. Buy and hold. Buy calls when the price is right.
πŸ‘οΈ0
Cat Cat 3 years ago
Ouch...LoL
πŸ‘οΈ0
Gpheart2016 Gpheart2016 3 years ago
EDIT has had a huge sell-off but should soon hit bottom. I can see a huge rebound starting within the next few days.
πŸ‘οΈ0
Kwl1 Kwl1 3 years ago
News out today ubx
πŸ‘οΈ0
Fress Fress 3 years ago
Added 2000 shares at 70.80 & 70.90


$EDIT
πŸ‘οΈ0
Fress Fress 4 years ago
Genome Stocks-Gene Editing.
$BEAM 5 billion market cap ARKG ETD
$EDIT 5.1 billion market cap ARKG ETF
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders ARKG ETF


$EDIT
πŸ‘οΈ0
Fress Fress 4 years ago
edit Looking for a $100.00 floor soon this stock is a beast along with beam. HGEN looks great too most people don't know they are a gene editing angle to there company besides monoclonal antibodies platform space which is being gobbled up by big pharma


$EDIT 5.2 Billion market cap
$Beam 5.5 market cap
$HGEN 800 million market cap phase 3 CV-19


$EDIT

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $EDIT Video Chart 12-21-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Gpheart2016 Gpheart2016 4 years ago
Yes, no sympathy for the short sellers, but I love them for the profits they are bringing to us.
πŸ‘οΈ0
go_glortho go_glortho 4 years ago
Good call on the Short Squeeze. I've been following EDIT for a while and with no news on EDIT-101 or EDIT-301, the Shorts may be the driving force behind the price run up right now. As of about a month ago, about 18% of shares were short. Not a great place to be! And frankly, I don't have a lot of sympathy....
πŸ‘οΈ0
Gpheart2016 Gpheart2016 4 years ago
CRSPR stocks are hot indeed! This continued price explosion in EDIT could be influenced by:
1. Work in sickle cell disease
2. Progress in hereditary blindness. Block buster news soon?
3. Short squeeze???
4. Any buyout rumors?
I have been on this stock for a while and took profits on calls way too early. I’m going to hold this stock. This technology will lead to a $500 or $1000 stock in the future.
πŸ‘οΈ0
MWM MWM 4 years ago
Let's just say the CRSPR sector is hot! $EDIT $SGMO $CRSP $BLUE $BEAM $NTLA











πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $EDIT Video Chart 12-10-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Gpheart2016 Gpheart2016 4 years ago
It looks like EDIT has become stock of the year. It took a while but was worth holding. I have sold only a few shares for profit and expect to hold on for now anticipating 500% upside in next few years. Options have also paid out handsomely . I looked at buying more May $60 calls but the premium seemed too high.
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
Robust Pre-Clinical Results and Large-Scale Manufacturing Process for EDIT-301: An Autologous Cell Therapy for the Potential Treatment of SCD https://www.editasmedicine.com/wp-content/uploads/2020/12/EDIT-301-ASH-Poster.pdf

Preclinical Development of EDIT-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment https://www.editasmedicine.com/wp-content/uploads/2020/12/Editas-ASH_EDIT-201-HDNK.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
SITC poster https://www.editasmedicine.com/wp-content/uploads/2020/11/EDIT-201_ET30322_SITC_2020.pdf
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock